A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

To join this study, you need to have non-small cell lung cancer that has spread to other parts of your body. You should have already tried other standard treatments for your cancer, or not be able to have them. This includes chemotherapy and other targeted therapies, depending on your specific cancer type. If your cancer has certain genetic changes (like EGFR mutations), you would need to have progressed on other treatments meant for those changes.

Your cancer must show at least one area that can be measured by scans, and you should generally be well enough to take part, meaning you can carry out most everyday activities without much trouble.

There are also some reasons why you might not be able to join. For example, if you have other serious uncontrolled health problems like diabetes, an active infection, or a bleeding disorder. The doctors will check all of these things carefully to make sure the study is safe for you.

If you join this study, you would receive the new combination of medications, amivantamab and cetrelimab. Initially, the study focuses on finding the right dose, so the exact dose you receive might vary until it's established. The research team will regularly monitor your health very closely with blood tests, scans, and physical examinations to see how you're responding to the treatment and to keep an eye on any side effects. You'll have regular hospital visits for these check-ups and to receive your medication. The total duration of your participation would depend on how well the treatment works for you and how you tolerate it, with ongoing follow-up after the treatment phase ends.